is a leading developer of ready-to-use kits for biomedical research. We also provide fast, accurate and affordable genomics, proteomics and mass spectrometry services using state-of-the-art technologies. Through strategic relationships between ITSIBIO and a number of reputable companies, our clients may also have access to QuantiGene products, custom ELISA kits, DNA/protein arrays and products for DNA storage at room temperature at a special price.
To provide state-of-the-art bioanalytical solutions to the global scientific community. ITSI-Biosciences will help its partners succeed by providing the highest quality service at a competitive price and turn-around time.
ITSIBIO strictly maintains good laboratory practices (GLP) and operates in accordance with the highest expected standards of education, quality assurance, quality control and safety. ITSIBIO fosters a climate that encourages innovation, dedication, hard work and diligence amongst staff and constantly rewards staff accordingly.
WHO WE SERVE
ITSIBIO was specifically established to provide integrated genomics, proteomics and biomarker discovery/validation services to independent investigators and research groups who need to generate high quality results at a competitive price and turn around time.
ITSIBIO will work with researchers from: Universities, Academic medical centers, Research institutes, Biotechnology companies and Pharmaceutical companies.
All projects are handled professionally and discreetly by senior and highly experienced scientists who constantly interact with the client via sophisticated web-based tools. The dedication and flexibility of the staff is unparalleled and the fact that ITSIBIO’s approach is solutions-oriented means that all partners get the maximum possible return on investment.
ITSIBIO Corporate headquarters is in Johnstown PA, USA, where state-of-the art equipment and analytical tools have been assembled to provide the highest level and quality of genomics, proteomics and biomarker discovery/validation services currently possible. The facility is 7 miles from the John P. Murtha Johnstown Airport and less than 100 miles from Pittsburgh, PA, 160 miles from Baltimore, MD and Washington DC.
All analytical projects are carefully designed by professionals and carried out by ITSIBIO senior and highly experienced scientists, who constantly interact with the client via sophisticated and secure web-based tools.
ITSIBIO serves academic institutions, military organizations, analytical laboratories, biotechnology and biopharmaceutical industries. Our key clients include:
- GE Healthcare, Piscataway, NJ.
- Georgetown University, Washington DC.
- Immunotope Inc, Doylestown PA.
- LifeLab, Durban, South Africa.
- Michigan State University, East Lansing, MI.
- Moffitt Cancer Center, Tampa, FL.
- NanoDrop Technologies, Wilmington, DE.
- National Cancer Institute, Bethesda, MD.
- National Institutes of Health, Bethesda, MD.
- Nigerian Army Medical Corps.
- Nigerian Defense Headquarters, Abuja, Nigeria.
- Penn State University Cancer Center, Hershey, PA.
- Texas Southern University, Houston, TX.
- Thomas Jefferson University, Philadelphia, PA.
- University of Houston, Houston, TX.
- USDA, Washington, DC.
ITSI-Biosciences serves as the extension of the laboratory of our partners. This unique relationship gives the partner access to high throughput state-of-the-art instrumentation, databases and expertise needed to be competitive and to succeed.
Each partner is provided a password-protected workbench termed workspace via a secure web-based interface that allows them private and unrestricted access to Itsibio remotely. This unique workspace can be visited at any time and from any location with internet access to:
- Monitor the status & progress of projects.
- Exchange information with the project manager and scientists.
- Download project related information, such as raw data, summary report, and methods used.
|Robert Clarke, PhD/D Sc||Professor of Oncology and Physiology & Biophysics, W405A Research Bldg, Georgetown University School of Medicine, Washington DC.|
|Emanuel F. Petricoin, PhD||Professor & Co-Director, Center for Applied Proteomics and Molecular Medicine, Department of Molecular and Microbiology, George Mason University, Manassas VA.|
|Barton Slatko,PhD||DNA Sequencing Group, Molecular Parasitology Division, New England Biolabs, Inc. Ipswich, MA.|
|David Friedman, PhD||Associate Director, Proteomics Laboratory, Mass Spectrometry Research Center, Vanderbilt University, Nashville, TN.|
|Carl Baker, MD/PhD||Chief, CRTS/BRL, National Cancer Institute, National Institutes of Health, Bethesda, MD.|
|James Lyons-Weiler, PhD||Scientific Director, Bioinformatics Analysis Core, Genomics and Proteomics Core Laboratories, Adjunct Faculty, Departments of Biomedical Informatics and Pathology.|
|Roderick V. Jensen, PhD||Alton Brann Distinguished Professor of Physics, Biology, and Mathematics, and Director of the Center for Environmental Health, Science, and Technology, University of Massachusetts Boston, Boston MA.|